Polymorphic forms of bisoprolol fumarate: preparation and characterization
3. Haleblian JK, McCrone W. Pharmaceutical applications of
polymorphism. J Pharm Sci. 1969;58:911–29.
transition behaviors of gestodene polymorphs and amorphous
phase. J Therm Anal Calorim. 2017;127:1533–42.
4. Grant DJW. Theory and origin of polymorphism. Drugs Pharm
Sci. 1999;95:1–33.
21. Strickland WA. Study of water vapour sorption by pharmaceu-
tical powders. J Pharm Sci. 1962;51:310–4.
5. Fabbiani FPA, Pulham CR. High-pressure studies of pharma-
ceutical compounds and energetic materials. Chem Soc Rev.
2006;35:932–42.
22. Giron D, Goldbronn C, Mutz M, Pfeffer S, Piechon P, Schwab P.
Solid state characterizations of pharmaceutical hydrates. J Therm
Anal Calorim. 2002;68:453–65.
6. Karpinski PH. Polymorphism of active pharmaceutical ingredi-
ents. Chem Eng Technol. 2006;29:233–8.
7. Brittain HG. Polymorphism and solvatomorphism. J Pharm Sci.
2011;100:1260–79.
8. Brittain HG, Fiese EF. Effects of pharmaceutical processing on
drug polymorphs and solvates. Drugs Pharm Sci.
1999;95:331–61.
23. Brittain HG. The impact of polymorphism on drug development:
a regulatory viewpoint. Am Pharm Rev. 2000;3(67–68):70.
24. Pfeffer-Hennig S, Piechon P, Bellus M, Goldbronn C, Tedesco E.
Physico-chemical characterization of an active pharmaceutical
ingredient. J Therm Anal Calorim. 2004;77:663–79.
25. Giron D, Mutz M, Garnier S. Solid-state of pharmaceutical
compounds. J Therm Anal Calorim. 2004;77:709–47.
26. ICH Harmonized Tripartite Guideline; Specifications: test pro-
cedures and acceptance criteria for new drug substances and new
drug products: chemical substances. Q6A. 1999.
9. Chieng N, Rades T, Aaltonen J. An overview of recent studies on
the analysis of pharmaceutical polymorphs.
Biomed. 2011;55:618–44.
J Pharmaceut
10. Hilfiker R. Polymorphism: in the pharmaceutical industry.
Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA; 2006.
11. Rosenstein S, Lamy PP. Polymorphism. Am J Hosp Pharm.
1969;26:598–601.
12. Brittain HG, Grant DJW. Effects of polymorphism and solid-state
solvation on solubility and dissolution rate. Drugs Pharm Sci.
1999;95:279–330.
27. Giron D. Monitoring of polymorphism—from detection to
quantification. Eng Life Sci. 2003;3:103–12.
28. Jonas R, Becker KH, Enenkel HJ, Minck K, Schliep HJ. Phe-
noxy-amino-propanole und Verfahren zu ihrer Herstellung. 1976.
DE2645710 A1.
29. European Pharmacopoeia (Ph. Eur.) 9th Edition (9.0), Mono-
graphs, Bisoprolol Fumarate; 2016.
¨
13. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical
30. U. S. Pharmacopoeia National Formulary (USP 40 NF 35), USP
Monographs, Bisoprolol Fumarate; 2017.
basis for a biopharmaceutics drug classification: the correlation of
in vitro drug product dissolution and in vivo bioavailability.
Pharm Res. 1995;12:413–20.
31. Ramirez E, Laosa O, Guerra P, Duque B, Mosquera B, Borobia
AM, Lei SH, Carcas AJ, Frias J. Acceptability and characteristics
of 124 human bioequivalence studies with active substances
classified according to the Biopharmaceutic Classification Sys-
tem. Br J Clin Pharmacol. 2010;70:694–702.
32. Gureeva SM. Bioavailability research of solid medicinal forms by
the example of bisoprolol fumarate tablets in relation to the
biopharmaceutical classification system. News Pharm.
2014;2:10–3.
33. CharooNA, ShamsherAAA, LianLY, Abrahamsson B, Cristofoletti
R, Groot DW, Kopp S, Langguth P, Polli J, Shah VP, Dressman J.
Biowaiver monograph for immediate-release solid oral dosage
forms: bisoprolol fumarate. J Pharm Sci. 2014;103:378–91.
34. Greenspan L. Humidity fixed points of binary saturated aqueous
solutions. J Res NBS A Phys Chem. 1977;81A:89–96.
35. Mangin D, Puel F, Veesler S. Polymorphism in processes of
crystallization in solution: a practical review. Org Process Res
Dev. 2009;13:1241–53.
14. Waiver of In Vivo Bioavailability and Bioequivalence Studies for
Immediate-Release Solid Oral Dosage Forms Based on a Bio-
pharmaceutics Classification System (Guidance for Industry).
U. S. Department of Health and Human Services, Food and Drug
Administration, Center for Drug Evaluation and Research
Accessed 17 Jan 2018.
15. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP,
Shah VP, Lesko LJ, Chen ML, Lee VHL, Hussain AS. Bio-
pharmaceutics classification system: the scientific basis for bio-
waiver extensions. Pharm Res. 2002;19:921–5.
16. Burger A, Ramberger R. On the polymorphism of pharmaceuti-
cals and other molecular crystals. I. Theory of thermodynamic
rules. Microchim Acta. 1979;2:259–71.
17. Burger A, Ramberger R. On the polymorphism of pharmaceuti-
cals and other molecular crystals. II. Applicability of thermody-
namic rules. Microchim Acta. 1979;2:273–316.
´
´
36. Baka E, Comer JEA, Takacs-Novak K. Study of equilibrium
solubility measurement by saturation shake-flask method using
hydrochlorothiazide as model compound. J Pharm Biomed.
2008;46:335–41.
18. Burger A. Thermodynamic and other aspects of the polymor-
phism of drugs. Pharm Int. 1982;3:158–63.
´
37. Dinya Z. Infrared spectroscopy (in Hungarian). Tankonyvkiado:
Kossuth Lajos University (Debrecen), Faculty of Natural Sci-
ences; 1981.
2018.
¨
19. Djellouli F, Dahmani A, Hassani A. Characterization of the
polymorph changes in Trimethoprim. J Therm Anal Calorim.
2017;130:1585–91.
20. Wang LY, Zhu L, Sha ZL, Li XC, Wang YF, Yang LB, Zhao XY.
Characterization, thermal stability, and solid-state phase
123